Health Canada — Medical Devices · Canada · 2018-07-05 · Type I
🏛Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked above. No AI-generated text appears on this page. How we use AI →
Reported risk: There is a potential for loss of high voltage and anti-tachycardia pacing therapy in entrust Implantable Cardioverter Defibrillators (ICDS) as they near Elective Replacement Indicator (ERI) voltage. Under certain circumstances, the device may display an immediate End Of Life (EOL) observation with no prior ERI alert. Though no ERI alert is triggered there may not be enough remaining battery capacity to charge the high voltage circuits, resulting in an excessive charge time EOL observation, leading to a loss of high voltage and anti-tachycardia pacing therapy. Bradycardia therapies will continue to operate as expected.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.